Skip to main content
OpenTrials
Completed

NCT Number: NCT03212261

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

About this study

The Relaxation Response Resiliency Program, or 3RP, was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine. The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.

The 3RP has not yet been carried out with individuals who have recently completed treatment for lymphoma. As such, the investigators have adapted the standard 3RP program to target the specific needs of lymphoma patients who are transitioning off active treatment. The investigators are conducting this study to see if the adapted program, the 3RP-Lymphoma, is effective at reducing stress and stress-related symptoms for people who have completed treatment for lymphoma within the past two years. To develop the 3RP-Lymphoma, the investigators conducted interviews with patients who had recently completed treatment to learn about their experiences and their preferences for topics they would want to include in a program tailored to their specific needs. The current phase of the feasibility study will examine if the adapted program is feasible, acceptable, and helps promote stress management among lymphoma survivors who are in the early stages of completing cancer treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-64
  • Within 2 years post-treatment completion for lymphoma
  • English speaking
  • Able and willing to provide informed consent
  • Cancer treatment or follow-up for lymphoma at the MGH Cancer Center

Exclusion criteria

  • Unwilling or unable to participate in the study
  • Unable to speak or read English
  • Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI)
  • Unwilling or unable to participate in group 3RP sessions delivered via the Partners Telehealth videoconferencing software
  • Participation in qualitative interview during Phase 1 (DF/HCC 16-396)

Treatment and study plan

3RP-Lymphoma

Behavioral

An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.

Other names: Relaxation Response Resiliency Program for Lymphoma

Primary outcomes

  1. Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions

    Time frame: 1 month after completing the 3RP-Lymphoma program

    The investigators will evaluate program feasibility by examining rates of treatment completion. Participants who complete at least 75% of the treatment sessions will be identified as treatment completers.

  2. Number of Participants Who Found the 3RP Program Acceptable

    Time frame: 1 month after completing the 3RP-Lymphoma program

    Acceptability will be assessed at the one-month follow up data collection period with five questions on the 3RP acceptability questionnaire rated on a 4-point Likert scale (1=not at all to 4=very much); higher scores mean higher levels of acceptability.

Secondary outcomes

  1. Number of Participants Who Were Eligible to Provide and Provided Hair Cortisol Samples

    Time frame: 1 month after completing the 3RP-Lymphoma program

    The investigators will explore the feasibility and acceptability of collecting hair samples to examine levels of cortisol, a stress biomarker.

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • American Cancer Society, Inc.

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jul 11, 2017
Registry last updated
Nov 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.